{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T21:03:18Z","timestamp":1790024598493,"version":"4.0.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:00:00Z","timestamp":1589155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-020-0321-6","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T17:10:30Z","timestamp":1589217030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Venetoclax for the treatment of translocation (11;14) AL amyloidosis"],"prefix":"10.1038","volume":"10","author":[{"given":"M. Hasib","family":"Sidiqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah S.","family":"Al Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed A.","family":"Aljama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilson I.","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis K.","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taxiarchis V.","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam A.","family":"Hobbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha Q.","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald S.","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne R.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,11]]},"reference":[{"key":"321_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-018-0080-9","volume":"8","author":"MA Gertz","year":"2018","unstructured":"Gertz, M. A. Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J. 8, 44 (2018).","journal-title":"Blood Cancer J."},{"key":"321_CR2","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1200\/JCO.2017.76.9554","volume":"36","author":"MH Sidiqi","year":"2018","unstructured":"Sidiqi, M. H. et al. Stem cell transplantation for light chain amyloidosis: decreased early mortality over time. J. Clin. Oncol. 36, 1323\u20131329 (2018).","journal-title":"J. Clin. Oncol"},{"key":"321_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1016\/j.bbmt.2015.10.010","volume":"22","author":"T Sher","year":"2016","unstructured":"Sher, T., Dispenzieri, A. & Gertz, M. A. Evolution of hematopoietic cell transplantation for immunoglobulin light chain amyloidosis. Biol. Blood Marrow Transplant. 22, 796\u2013801 (2016).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"321_CR4","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nm.3048","volume":"19","author":"AJ Souers","year":"2013","unstructured":"Souers, A. J. et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat. Med. 19, 202\u2013208 (2013).","journal-title":"Nat. Med."},{"key":"321_CR5","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.3324\/haematol.2016.160408","volume":"102","author":"C Touzeau","year":"2017","unstructured":"Touzeau, C. et al. Deep and sustained response after venetoclax therapy in a patient with very advanced refractory myeloma with translocation t(11;14). Haematologica 102, e112\u2013e114 (2017).","journal-title":"Haematologica"},{"key":"321_CR6","doi-asserted-by":"publisher","first-page":"2401","DOI":"10.1182\/blood-2017-06-788786","volume":"130","author":"S Kumar","year":"2017","unstructured":"Kumar, S. et al. Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma. Blood 130, 2401\u20132409 (2017).","journal-title":"Blood"},{"key":"321_CR7","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1158\/1535-7163.MCT-15-0730","volume":"15","author":"EA Punnoose","year":"2016","unstructured":"Punnoose, E. A. et al. Expression profile of BCL-2, BCL-XL, and MCL-1 predicts pharmacological response to the BCL-2 selective antagonist Venetoclax in multiple myeloma models. Mol. Cancer Ther. 15, 1132\u20131144 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"321_CR8","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1038\/leu.2016.369","volume":"31","author":"E Muchtar","year":"2017","unstructured":"Muchtar, E. et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia 31, 1562\u20131569 (2017).","journal-title":"Leukemia"},{"key":"321_CR9","doi-asserted-by":"publisher","first-page":"3735","DOI":"10.1182\/blood.V99.10.3735","volume":"99","author":"R Fonseca","year":"2002","unstructured":"Fonseca, R. et al. Myeloma and the t(11;14)(q13;q32); evidence for a biologically defined unique subset of patients. Blood 99, 3735\u20133741 (2002).","journal-title":"Blood"},{"key":"321_CR10","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1182\/blood.V98.7.2266","volume":"98","author":"SR Hayman","year":"2001","unstructured":"Hayman, S. R. et al. Translocations involving the immunoglobulin heavy-chain locus are possible early genetic events in patients with primary systemic amyloidosis. Blood 98, 2266\u20132268 (2001).","journal-title":"Blood"},{"key":"321_CR11","doi-asserted-by":"publisher","first-page":"e135","DOI":"10.3324\/haematol.2017.183749","volume":"103","author":"N Leung","year":"2018","unstructured":"Leung, N., Thome, S. D. & Dispenzieri, A. Venetoclax induced a complete response in a patient with immunoglobulin light chain amyloidosis plateaued on cyclophosphamide, bortezomib and dexamethasone. Haematologica 103, e135\u2013e137 (2018).","journal-title":"Haematologica"},{"issue":"Suppl","key":"321_CR12","doi-asserted-by":"publisher","first-page":"e19538","DOI":"10.1200\/JCO.2019.37.15_suppl.e19538","volume":"37","author":"FL Bras","year":"2019","unstructured":"Bras, F. L. et al. Venetoclax induces sustained complete responses in refractory\/relapsed patients with cardiac AL amyloidosis. J. Clin. Oncol. 37(Suppl.), e19538\u2013e19538 (2019).","journal-title":"J. Clin. Oncol."},{"key":"321_CR13","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz, M. A. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18-22 April 2004. Am. J. Hematol. 79, 319\u2013328 (2005).","journal-title":"Am. J. Hematol."},{"key":"321_CR14","doi-asserted-by":"publisher","first-page":"4541","DOI":"10.1200\/JCO.2011.37.7614","volume":"30","author":"G Palladini","year":"2012","unstructured":"Palladini, G. et al. New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes. J. Clin. Oncol. 30, 4541\u20134549 (2012).","journal-title":"J. Clin. Oncol."},{"key":"321_CR15","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1200\/JCO.2011.38.5724","volume":"30","author":"S Kumar","year":"2012","unstructured":"Kumar, S. et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J. Clin. Oncol. 30, 989\u2013995 (2012).","journal-title":"J. Clin. Oncol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0321-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0321-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0321-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,5]],"date-time":"2022-12-05T14:28:28Z","timestamp":1670250508000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-020-0321-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,11]]},"references-count":15,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["321"],"URL":"https:\/\/doi.org\/10.1038\/s41408-020-0321-6","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,11]]},"assertion":[{"value":"18 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.H.S., A.S.A., D.J., M.A.A., T.V.K., R.W., E.M., M.A.H., R.S.G., S.R.H., S.V.R., N.L., W.I.G., F.K.B.: none. M.A.G.: consultancy (Milleniu) and honoraria (Celgene, Millenium, Onyx, Novartis, Smith Kline, Prothena, Ionis); M.Q.L.: research funding (Celgene); D.D.: research funding (Karyopharm Therapeutics, Amgen, and Millenium Pharmaceuticals); S.K.K.: consultancy (Celgene, Millennium, Onyx, Janssen, and BMS), and research funding (Celgene, Millennium, Novartis, Onyx AbbVie, Janssen, and BMS). A.D.: research funding (Celgene, Millennium, Pfizer, and Janssen), Travel grant (Pfizer). R.F.: stock and other ownership interests: Adaptive Biotechnologies; Honoraria: Celgene, Bristol-Myers Squibb, Bayer, Amgen, Janssen, Kite Pharma, Merck Sharp & Dohme, Juno Therapeutics, Takeda, AbbVie, Aduro Biotech, Sanofi; consulting or advisory role: Celgene, Bristol-Myers Squibb, Bayer, Amgen, Janssen, AbbVie, Kite Pharma, Merck Sharp & Dohme, Juno Therapeutics, Takeda, Aduro Biotech, Sanofi; patents, royalties, other intellectual property: patent for the prognostication of multiple myeloma based on genetic categorization of the disease. Travel, accommodations, expenses: multiple. P.K.: research funding (Takeda, Sanofi, AbbVie and Amgen).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"55"}}